Advanced Cell Technology, Inc. gets FDA approval to use stem cells as a possible treatment for Stargardt's disease, a inherited juvenile type of macular degeneration.
Clinical trials for RPE replacement therapy for Stargardt's disease and dry AMD have begun. The study will assess the safety of replacing stem-cell derived RPE cells in humans.